Connect
← Return to Any of you heard about the inhibitor RMC-7977?
Discussion
Any of you heard about the inhibitor RMC-7977?
Pancreatic Cancer | Last Active: Apr 26 3:45pm | Replies (16)Comment receiving replies
@annsant, from the abstract that @mayoconnectuser1 provided it appears that these promising new treatments are still in early stages. So far testing has been in vitro (in petri dishes) and in vivo (in mice). Next steps will be multiple phases of human trials.
Tagging @stageivsurvivor, who may have further insights.
Replies to "@annsant, from the abstract that @mayoconnectuser1 provided it appears that these promising new treatments are still..."
Connect
There are two trials that are unique in that they are “pan” KRAS targeted therapies. They have the capability of targeting all KRAS variants, not just a specific one. Revolution Medicine’s RMC-6236 has some limited positions open. It is a phase Ia/Ib dose escalation study. This trial filled fast. There are some limited spaces open.
https://classic.clinicaltrials.gov/ct2/show/NCT05379985Another trial drug that also is a “pan” KRAS targeted therapy is RSC-1255 made by Rascal Therapeutics. This is in a phase Ia/Ib dose escalation phase and recruiting.
https://classic.clinicaltrials.gov/ct2/show/NCT04678648
Both of these drugs act upstream of the KRAS variants by interrupting the cell signaling pathway at the RAS gene one level above. By blocking the cell signaling pathway there, all variants below it would be prevented from receiving a signal to continue growth and proliferation. As a result, the cell enters apoptosis (programmed cell death) and dies.